FIA
BBIO icon

FNY Investment Advisers’s BridgeBio Pharma BBIO Stock Holding History

FNY Investment Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-89
Closed -$2K – 736
2024
Q4 		$2K Buy
89
+40
+82% +$1.03K ﹤0.01% 578
2024
Q3 		$1K Sell
49
-56
-53% -$1.47K ﹤0.01% 618
2024
Q2 		$2K Buy
+105
New +$2.87K ﹤0.01% 392
2024
Q1 		– Sell
-135
Closed -$5K – 676
2023
Q4 		$5K Buy
+135
New +$4.05K 0.01% 349
2023
Q2 		– Sell
-211
Closed -$3K – 534
2023
Q1 		$3K Buy
+211
New +$2.46K ﹤0.01% 426

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FNY Investment Advisers's BBIO Position: Q3 2025 in Review

FNY Investment Advisers sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 3,500 shares — an estimated $151K sold.

FNY Investment Advisers first reported a position in BBIO in Q2 2019 and held it in 9 quarters. The position peaked at $391K in Q1 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • FNY Investment Advisers reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 3,500 BridgeBio Pharma shares in Q3 2025, an estimated $151K.
  • FNY Investment Advisers first reported a position in BridgeBio Pharma in Q2 2019 and held it in 9 quarters.
  • FNY Investment Advisers's BridgeBio Pharma position peaked at $391K in Q1 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on FNY Investment Advisers's 13F filing for Q3 2025, filed 15 Dec 2025.